Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 4/20 | 0.55 |
| ▸ | THRA | P10827 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.50 |
| ▸ | RARB | P10826 | 4/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8648767 | 0.93 | PLA2G2A (0.66) | PLA2G2ATHRBTHRATP53TSHR | |
| SCHEMBL8231851 | 0.90 | THRB (0.50) | PLA2G2ATHRBTHRATP53TSHR | |
| SCHEMBL8062575 | 0.84 | PTPN1 (0.60) | PLA2G2ATHRBTHRATP53TSHR | |
| SCHEMBL8645733 | 0.84 | PLA2G2A (0.59) | PLA2G2ATHRBTHRATP53TSHR | |
| SCHEMBL13215464 | 0.84 | PLA2G2A (0.57) | PLA2G2ATP53TSHRPLA2G4BRARB | |
| SCHEMBL10084150 | 0.83 | THRB (0.52) | PLA2G2ATHRBTHRA | |
| SCHEMBL10364486 | 0.82 | CYP3A4 (0.47) | PLA2G2ATHRBTHRATP53TSHR | |
| SCHEMBL10658494 | 0.82 | PTPN11 (0.46) | PLA2G2ATHRBTHRATP53TSHR | |
| SCHEMBL5104447 | 0.81 | PLA2G2A (0.54) | PLA2G2ATP53TSHRPLA2G4BRARB | |
| SCHEMBL1023516 | 0.79 | THRA (0.59) | THRBTHRATP53TSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| EP-1632479-B1 | Pharmaceutical compositions comprising CCR5 antagonizing piperazine derivatives | SCHERING CORP (US) | 2011-01-12 | — | — | EP | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-7384944-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| WO-2007050375-A2 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR2 | PLA2G2A 3608/4885THRB 1660/4885THRA 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.